Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study-Reference-Cited by-同舟云学术

Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study

Published:2023-12 Issue: Volume:35 Page:100747
ISSN:2666-7762
Container-title:The Lancet Regional Health - Europe
language:en
Short-container-title:The Lancet Regional Health - Europe

Author:

Evans Rachael A.,Dube Sabada,Lu Yi,Yates Mark,Arnetorp Sofie,Barnes Eleanor,Bell Samira^ORCID,Carty Lucy,Evans Kathryn,Graham Sophie,Justo Nahila^ORCID,Moss Paul,Venkatesan Sudhir^ORCID,Yokota Renata,Ferreira Catia,McNulty Richard,Taylor Sylvia,Quint Jennifer K.^ORCID

Publisher

Elsevier BV

Subject

Health Policy,Oncology,Internal Medicine

Reference43 articles.

1. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis;Lancet,2023

2. COVID-19 severity from Omicron and Delta SARS-CoV-2 variants;Wrenn;Influenza Other Respir Viruses,2022

3. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study;Wolter;Lancet,2022

4. Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study;Ward;BMJ,2022

5. Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019-positive patients;Hu;Clin Microbiol Infect,2023

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Anti-SARS-CoV-2 Vaccination on Disease Severity and Clinical Outcomes of Individuals Hospitalized for COVID-19 Throughout Successive Pandemic Waves: Data from an Italian Reference Hospital;Vaccines;2024-09-06

2. COVID-19 in the immunocompromised host;COVID-19: An Update;2024-09-01

3. Management of severe COVID-19 in the ICU;COVID-19: An Update;2024-09-01

4. Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection;Journal of Virology;2024-08-29

5. Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France;Human Vaccines & Immunotherapeutics;2024-08-14